Business Context and Reporting Period
This Form 8-K is a current report filed by Prelude Therapeutics Inc. (PRLD) on September 17, 2021, regarding an event that occurred on September 16, 2021. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel change and does not contain financial statements or performance data.
Material Changes
The material change reported is the departure of a senior executive. Christopher Pierce has resigned as Executive Vice President and Chief of Business Operations. His resignation is effective September 30, 2021, to pursue another employment opportunity.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future strategy, specific risks, contingencies, or unusual items beyond the executive departure.
Key Facts for Investors to Verify
- Confirmation of the effective date of Christopher Pierce's resignation (September 30, 2021).
- Details regarding the succession plan or interim leadership for the Chief of Business Operations role.
- Whether this departure impacts ongoing clinical trials or business development activities.